Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an update.
Resmed Inc. reported strong financial results for the third quarter of fiscal year 2025, with an 8% increase in revenue and a 14% rise in operating profit compared to the previous year. The company’s performance was driven by robust customer demand for its sleep devices, masks portfolio, and Residential Care Software business, resulting in a 9% revenue growth on a constant currency basis. Resmed’s strategic focus on expanding its market-leading value proposition in connected digital health contributed to a 140 basis point improvement in gross margin and double-digit earnings per share growth. The company’s commitment to increasing patient flow and awareness among healthcare providers underscores its ongoing efforts to enhance its industry positioning and stakeholder value.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
Resmed Inc. operates in the healthcare industry, focusing on providing innovative solutions for sleep health and breathing disorders. The company is known for its best-in-class products and software solutions, which are recognized as the gold standard for care in connected digital health. Resmed is committed to addressing the needs of over 2.3 billion people globally with sleep and breathing health issues, as well as those requiring world-class healthcare software for home delivery.
YTD Price Performance: -10.66%
Average Trading Volume: 1,405,817
Technical Sentiment Signal: Hold
Current Market Cap: A$49.16B
See more insights into RMD stock on TipRanks’ Stock Analysis page.